FDA Division of Reproductive & Urologic Drug Products
Executive Summary
Review division may bear watching over the first weeks of 2000. Division Director Lisa Rarick, MD, is switching to the position of Office of Drug Evaluation II deputy director starting Jan. 18 (1"The Pink Sheet" Dec. 20, 1999, p. 25). The two-week delay between the start of the calendar year and the effective date of the appointment suggests that there may be some near-term pending actions for the division to complete